Roche AG, of Basel, Switzerland, presented new data from the LUTE/VERSE phase IIb studies investigating lebrikizumab in patients with severe uncontrolled asthma. The data showed that asthma attacks were reduced by 60 percent in lebrikizumab-treated patients with a high level of the biomarker periostin, compared to 5 percent in patients with a low level of periostin.